AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31646974 — intervention group
Group type: EXPERIMENTAL
Intervention: Paranasal air suction (three intermittent 10 sec suctions with 10 sec intervals)
Number of subjects: 56
Study 31646974 — intervention group
Group type: COMPARATOR
Intervention: Placebo air suction (no paranasal air suction)
Number of subjects: 56
Study 31646974 — intervention group
Group type: EXPERIMENTAL
Intervention: Paranasal air suction
Number of subjects: 56
Study 31646974 — intervention group
Group type: COMPARATOR
Intervention: Placebo air suction
Number of subjects: 56
Study 29992370 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg beloranib
Number of subjects: 153
Study 29992370 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg beloranib
Number of subjects: 153
Study 29992370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 26482098 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic sliders with static stretching (NS-SS)
Number of subjects: 60
Study 26482098 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic tensioners with static stretching (NT-SS)
Number of subjects: 60
Study 26482098 — intervention group
Group type: COMPARATOR
Intervention: Static stretching alone (SS)
Number of subjects: 60
Study 25393812 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent daily stress
Number of subjects: 138
Study 25393812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent daily stress
Number of subjects: 138
Study 23290219 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) + basic fibroblast growth factor (bFGF)
Number of subjects: 48
Study 23290219 — intervention group
Group type: COMPARATOR
Intervention: Negative pressure wound therapy (NPWT) alone
Number of subjects: 48
Study 20942911 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐to‐high intensity Nordic Walking (NW)
Number of subjects: 67
Study 20942911 — intervention group
Group type: COMPARATOR
Intervention: Supervised low‐intensity walking (LIW)
Number of subjects: 67
Study 16990449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (OF-IN)
Number of subjects: 20
Study 16990449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota
Number of subjects: 20
Study 16990449 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve Yakult
Number of subjects: 20
Study 16990449 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic L. casei Shirota + OF-IN
Number of subjects: 20
Study 16990449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10672149 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-base dentures
Number of subjects: 25
Study 10672149 — intervention group
Group type: COMPARATOR
Intervention: Resin-base dentures
Number of subjects: 25
Study 9090338 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-facilitated intervention (6 to 10 sessions)
Number of subjects: 37
Study 9090338 — intervention group
Group type: COMPARATOR
Intervention: Lecture intervention (2 lectures attended only by parents)
Number of subjects: 37
Study 1443508 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ketamine (2 mg/kg)
Number of subjects: 10
Study 1443508 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (1 mg/kg)
Number of subjects: 10
Study 1443508 — intervention group
Group type: EXPERIMENTAL
Intervention: Both racemic ketamine and S(+)‐ketamine
Number of subjects: 10
Study 3513810 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain-tablets (2.5 mg terbutaline sulphate, three times daily at 6 h intervals)
Number of subjects: 10
Study 3513810 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release tablets (5 mg terbutaline sulphate, every 12 h)
Number of subjects: 10
Study 31644933 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Story Memory Technique (mSMT)
Number of subjects: 16
Study 31644933 — intervention group
Group type: COMPARATOR
Intervention: placebo control
Number of subjects: 16
Study 30559336 — intervention group
Group type: EXPERIMENTAL
Intervention: PASP <35 mmHg
Number of subjects: 363
Study 30559336 — intervention group
Group type: COMPARATOR
Intervention: PASP ≥35 mmHg
Number of subjects: 363
Study 30559336 — intervention group
Group type: EXPERIMENTAL
Intervention: Time on dialysis
Number of subjects: 363
Study 30559336 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft failure
Number of subjects: 363
Study 27425582 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam conformal radiotherapy
Number of subjects: 545
Study 27425582 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance processes
Number of subjects: 545
Study 27425582 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to dose constraints in ProtecT
Number of subjects: 545
Study 24595567 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg BID
Number of subjects: 197
Study 24595567 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 197
Study 24595567 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg BID
Number of subjects: 197
Study 24595567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 23273255 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity isokinetic knee extensor resistance training (RT) for 8 weeks
Number of subjects: 64
Study 20420799 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 30
Study 20420799 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 30
Study 17196547 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefed group
Number of subjects: 64
Study 17196547 — intervention group
Group type: COMPARATOR
Intervention: Non-debriefed group (control)
Number of subjects: 64
Study 15886669 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS wound matrix plus compression therapy (n = 62)
Number of subjects: 120
Study 15886669 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy alone (n = 58)
Number of subjects: 120
Study 12629231 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi stimulation on
Number of subjects: 9
Study 12629231 — intervention group
Group type: COMPARATOR
Intervention: GPi stimulation off (15 to 120 minutes)
Number of subjects: 9
Study 12629231 — intervention group
Group type: COMPARATOR
Intervention: GPi stimulation off
Number of subjects: 9
Study 10320164 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketoprofen
Number of subjects: 54
Study 10320164 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 54
Study 8919739 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inserted vaginal tampons
Number of subjects: 69
Study 8919739 — intervention group
Group type: COMPARATOR
Intervention: Clinician-obtained endocervical swabs
Number of subjects: 69
Study 1862733 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 123
Study 1862733 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 123
Study 1862733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 30918350 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-chain fatty acids (butyrate and propionate)
Number of subjects: 0
Study 27905255 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative self-reflection
Number of subjects: 56
Study 27905255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruminative brooding
Number of subjects: 56
Study 27905255 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased self-criticism
Number of subjects: 56
Study 25872934 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 240
Study 25872934 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 240
Study 24035611 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane induction with 8% for 2 minutes then 2.5%
Number of subjects: 34
Study 24035611 — intervention group
Group type: COMPARATOR
Intervention: Target-controlled inhalation with a target end-tidal concentration of sevoflurane set at 2.5%
Number of subjects: 34
Study 21862911 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereophotogrammetry (SP)
Number of subjects: 10
Study 19132881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 27
Study 19132881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 27
Study 19132881 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline and Sertraline
Number of subjects: 27
Study 17568956 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive assessment
Number of subjects: 0
Study 17568956 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent assessment (Months 1-6)
Number of subjects: 0
Study 17568956 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief conditions
Number of subjects: 0
Study 17568956 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent assessment (Months 7-12)
Number of subjects: 0
Study 17568956 — intervention group
Group type: EXPERIMENTAL
Intervention: No reactivity effects
Number of subjects: 0
Study 16137089 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly loaded Brånemark System or Replace Select Tapered implants (Nobel Biocare AB)
Number of subjects: 20
Study 16137089 — intervention group
Group type: COMPARATOR
Intervention: Reference group treated according to a two‐stage protocol
Number of subjects: 20
Study 12097537 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Number of subjects: 119
Study 12097537 — intervention group
Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 119
Study 10430149 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered sonographic contrast agent (200, 400, 600, 800, or 1000 ml)
Number of subjects: 99
Study 10430149 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered sonographic contrast agent
Number of subjects: 99
Study 8538189 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO) at a dose of 0.25 gm/m2 per day
Number of subjects: 0
Study 8538189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8538189 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO)
Number of subjects: 0
Study 2142578 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms of ethinyl estradiol + 150 micrograms of desogestrel (Marvelon; n = 21)
Number of subjects: 40
Study 2142578 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms of ethinyl estradiol + 2 mg of cyproterone acetate (Diane-35; n = 19)
Number of subjects: 40
Study 2142578 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Marvelon and Diane-35)
Number of subjects: 40
Study 7011113 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol (20 mg)
Number of subjects: 0
Study 7011113 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol (30 mg)
Number of subjects: 0
Study 7011113 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (5 mg)
Number of subjects: 0
Study 7011113 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (200 mg)
Number of subjects: 0
Study 7011113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31204499 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective-efficacy enhanced intervention
Number of subjects: 86
Study 31204499 — intervention group
Group type: COMPARATOR
Intervention: Standard health education/walking group
Number of subjects: 86
Study 30253043 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 25 mg once daily for 72 weeks
Number of subjects: 0
Study 30253043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27183922 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia at FiO2: 0.125 (4200 m)
Number of subjects: 8
Study 27183922 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia at FiO2: 0.115 (4800 m)
Number of subjects: 8
Study 27183922 — intervention group
Group type: COMPARATOR
Intervention: Normobaric hypoxia at FiO2: 0.209 (SL)
Number of subjects: 8
Study 27183922 — intervention group
Group type: COMPARATOR
Intervention: Normobaric hypoxia at FiO2: 0.135 (3600 m)
Number of subjects: 8
Study 27137142 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg every 8 hours)
Number of subjects: 0
Study 27137142 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg every 8 hours)
Number of subjects: 0
Study 27137142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22855206 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (TA) 1,000 mg
Number of subjects: 8
Study 22855206 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 21342154 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane sedation
Number of subjects: 100
Study 21342154 — intervention group
Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 100
Study 19661927 — intervention group
Group type: EXPERIMENTAL
Intervention: Added potassium and calcium to cooking salt (10 mmol of potassium and 10 mmol of calcium).
Number of subjects: 325
Study 19661927 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-restricted diet (50-100 mmol per person per day).
Number of subjects: 325
Study 19661927 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 325
Study 16770213 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of a drain in the epidural space
Number of subjects: 50
Study 16770213 — intervention group
Group type: COMPARATOR
Intervention: No insertion of a drain
Number of subjects: 50
Study 16770213 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of a drain
Number of subjects: 50
Study 15322526 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-amyloid strategies (including secretase inhibition, amyloid-beta aggregation inhibition, immunotherapy)
Number of subjects: 0
Study 15322526 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotrophic or neuroprotective approaches
Number of subjects: 0
Study 15322526 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies based on epidemiological observation
Number of subjects: 0
Study 11253857 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amiodarone or sotalol
Number of subjects: 0
Study 11253857 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic drug therapy
Number of subjects: 0
Study 11253857 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis administered selectively to high-risk patients
Number of subjects: 0
Study 11253857 — intervention group
Group type: COMPARATOR
Intervention: Combination of rate control and anticoagulation with cardioversion if AF persists
Number of subjects: 0
Study 9141112 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg budesonide b.i.d. from Aiolos nebulizer
Number of subjects: 38
Study 9141112 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg budesonide b.i.d. from Pari LL nebulizer
Number of subjects: 38
Study 9141112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nebulizers
Number of subjects: 38
Study 7835809 — intervention group
Group type: COMPARATOR
Intervention: Current screening modalities of CA 125 and transvaginal ultrasonography
Number of subjects: 0
Study 7835809 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 0
Study 7835809 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant therapy
Number of subjects: 0
Study 7835809 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial participation
Number of subjects: 0
Study 7835809 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to information and specialists
Number of subjects: 0
Study 3432897 — intervention group
Group type: EXPERIMENTAL
Intervention: CIVETE technique (intravaginal culture of embryos)
Number of subjects: 100
Study 3432897 — intervention group
Group type: COMPARATOR
Intervention: Classic technique (control group, not detailed)
Number of subjects: 100
Study 30504515 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (200 μg or 300 μg)
Number of subjects: 1706
Study 30504515 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (5 mg)
Number of subjects: 1706
Study 26704612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine candidate (TDV)
Number of subjects: 360
Study 26704612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 25458886 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g/kg psyllium (n=12)
Number of subjects: 34
Study 25458886 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g/kg MgSO4 (n=10)
Number of subjects: 34
Study 25458886 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of psyllium and MgSO4 (n=12)
Number of subjects: 34
Study 23459131 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D teaching presentation
Number of subjects: 0
Study 23459131 — intervention group
Group type: COMPARATOR
Intervention: 2D traditional lecture
Number of subjects: 0
Study 19825504 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60-120 mg/day)
Number of subjects: 2069
Study 19825504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2069
Study 18786302 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60-mg loading dose, 10-mg maintenance dose for 7 days) with ranitidine (150 mg twice daily)
Number of subjects: 47
Study 18786302 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (600-mg loading dose, 75-mg maintenance dose for 7 days) with ranitidine (150 mg twice daily)
Number of subjects: 47
Study 18786302 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel alone (without ranitidine)
Number of subjects: 47
Study 18786302 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel alone (without ranitidine)
Number of subjects: 47
Study 16095423 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training plus balanced low-energy diet (900-1200 cal)
Number of subjects: 82
Study 16095423 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 82
Study 11942372 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine, 0.2 mmol/kg bodyweight administered as sequential injections of 0.05, 0.05 and 0.1 mmol/kg over a 20-min period
Number of subjects: 74
Study 11942372 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine, 0.2 mmol/kg bodyweight administered as sequential injections
Number of subjects: 74
Study 10026745 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day transurethral catheterization
Number of subjects: 126
Study 10026745 — intervention group
Group type: COMPARATOR
Intervention: 5-day transurethral catheterization
Number of subjects: 126
Study 10026745 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day transurethral catheterization (after excluding low rectum carcinoma)
Number of subjects: 126
Study 10026745 — intervention group
Group type: COMPARATOR
Intervention: 5-day transurethral catheterization (after excluding low rectum carcinoma)
Number of subjects: 126
Study 7747617 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate 200 mg/day
Number of subjects: 20
Study 7747617 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate 400 mg/day
Number of subjects: 20
Study 7747617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2282920 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg twice daily for 2 weeks
Number of subjects: 20
Study 2282920 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 20
Study 2282920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7321834 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% MVC
Number of subjects: 15
Study 7321834 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% MVC
Number of subjects: 15
Study 7321834 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% MVC
Number of subjects: 15
Study 7321834 — intervention group
Group type: COMPARATOR
Intervention: 1.00 MVC (non-fatigued state)
Number of subjects: 15
Study 27792398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention with grief intervention module (12 therapy sessions over six months)
Number of subjects: 273
Study 27792398 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 273
Study 27738234 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal approach including telephone contacts, screening for adverse sequelae, written information, home visits, review of goal achievement, and further referral to relevant health services.
Number of subjects: 110
Study 27738234 — intervention group
Group type: COMPARATOR
Intervention: Standard management as determined by the treating team (Control group).
Number of subjects: 110
Study 25082808 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 527
Study 25082808 — intervention group
Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 527
Study 22083873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 2164
Study 22083873 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2164
Study 19577405 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary reinforcement for attendance ($25 to $30)
Number of subjects: 175
Study 19577405 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment sessions (control)
Number of subjects: 175
Study 18450989 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g/kg dietary protein intake
Number of subjects: 34
Study 18450989 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g/kg dietary protein intake
Number of subjects: 34
Study 18450989 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dietary groups
Number of subjects: 34
Study 15811982 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus supervised aerobic exercise training for 35 minutes 3 times per week for 16 weeks
Number of subjects: 134
Study 15811982 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus weekly 1.5‐hour stress management training for 16 weeks
Number of subjects: 134
Study 15811982 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study 12529549 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34(+) enrichment
Number of subjects: 18